Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer : Appraisal consultation committee papers
Cited by National Institute for Health and Care Excellence on
The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.